RxDoctor Payments Data

Johny Kuttab

Interventional Cardiology · Manchester, NHNPI 1366670754

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,961 of the $4,670 with a category attached, or 63.4%. 16 manufacturers reported payments, led by Abbott at 37.5% of the total. That places this record below the midpoint for interventional cardiology clinicians in NH, where the typical reported total is $5,309.

$4,670in general payments, 2019–2025

Across 73 payments — averaging $63.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Edwards Lifesciences$2K
  • Boston Scientific$348
  • Abiomed$221
  • Shockwave Medical, Inc$211
  • Novartis$150
  • plus $447 from 10 others

What the payments were for

  • Travel & lodging$1,70837%
  • Food & beverage$2,96163%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,670 in reported general payments places this provider in the 45th percentile of 26 interventional cardiology providers in New Hampshire.

See all interventional cardiology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$125,326
Medicare patients
762
Services billed
1,693

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban164$239,216
XareltoRivaroxaban59$75,889
Repatha SureclickEvolocumab49$37,126
JardianceEmpagliflozin22$30,290
Ranolazine ErRanolazine31$4,391
Metoprolol Succinate322$3,698
Rosuvastatin Calcium145$2,660
Atorvastatin Calcium288$2,617
Diltiazem 24hr Er (Cd)Diltiazem Hcl36$1,946
Isosorbide Mononitrate ErIsosorbide Mononitrate87$1,755
ClopidogrelClopidogrel Bisulfate129$1,563
Tiadylt ErDiltiazem Hcl13$1,082
Lisinopril149$1,061
Flecainide Acetate23$888
Amlodipine Besylate147$848

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$35$239,216164 claims
Johnson & JohnsonXarelto$115$75,88959 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 26 interventional cardiology providers in New Hampshire.

Other interventional cardiology in Manchester

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →